Market Cap (In USD)
24.09 Million
Revenue (In USD)
-
Net Income (In USD)
-25.78 Million
Avg. Volume
1.02 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.34-2.95
- PE
- -
- EPS
- -
- Beta Value
- 1.335
- ISIN
- US19243B1026
- CUSIP
- 19243B102
- CIK
- 1455365
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Lisa Ricciardi
- Employee Count
- -
- Website
- https://www.cogrx.com
- Ipo Date
- 2021-10-08
- Details
- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
More Stocks
-
FMKEcograf Ltd
FMK
-
OMED
-
CSCCFCapstone Copper Corp.
CSCCF
-
0GC0
-
1578
-
CYDVFCentury Lithium Corp.
CYDVF
-
SIIS
-
LUMAXINDLumax Industries Limited
LUMAXIND